Eagle Pharmaceuticals (EGRX) Receiving Favorable Media Coverage, Study Shows

News headlines about Eagle Pharmaceuticals (NASDAQ:EGRX) have been trending positive this week, according to Accern Sentiment. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Eagle Pharmaceuticals earned a media sentiment score of 0.26 on Accern’s scale. Accern also gave headlines about the specialty pharmaceutical company an impact score of 45.5457852898722 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Several research firms have issued reports on EGRX. ValuEngine upgraded Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, October 2nd. Zacks Investment Research downgraded Eagle Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday. Mizuho reissued a “sell” rating and issued a $37.00 price target on shares of Eagle Pharmaceuticals in a report on Wednesday, November 8th. BidaskClub raised Eagle Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, December 2nd. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $75.00 price target (down previously from $81.00) on shares of Eagle Pharmaceuticals in a report on Thursday, November 9th. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the company. Eagle Pharmaceuticals presently has an average rating of “Hold” and a consensus price target of $62.33.

Shares of Eagle Pharmaceuticals (NASDAQ EGRX) opened at $62.56 on Friday. The company has a quick ratio of 5.15, a current ratio of 5.30 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $925.14, a PE ratio of 10.07 and a beta of 1.24. Eagle Pharmaceuticals has a twelve month low of $45.05 and a twelve month high of $97.15.

WARNING: “Eagle Pharmaceuticals (EGRX) Receiving Favorable Media Coverage, Study Shows” was first posted by Markets Daily and is the property of of Markets Daily. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at https://www.themarketsdaily.com/2018/01/12/eagle-pharmaceuticals-egrx-receiving-favorable-media-coverage-study-shows.html.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka.

Insider Buying and Selling by Quarter for Eagle Pharmaceuticals (NASDAQ:EGRX)

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply